scispace - formally typeset
J

Jaap W. Deckers

Researcher at Erasmus University Rotterdam

Publications -  273
Citations -  39450

Jaap W. Deckers is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Myocardial infarction & Heart failure. The author has an hindex of 68, co-authored 268 publications receiving 37766 citations. Previous affiliations of Jaap W. Deckers include European Society of Cardiology & Hannover Medical School.

Papers
More filters
Journal ArticleDOI

Stroke in Patients With Acute Coronary Syndromes Incidence and Outcomes in the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial

TL;DR: Higher heart rate was the most important baseline clinical predictor of nonhemorrhagic stroke, followed by older age, prior anterior myocardial infarction, prior stroke or transient ischemic attack, and diabetes mellitus, and these factors were used to develop a simple scoring nomogram that can predict the risk ofNonhemor rhagic stroke.
Journal ArticleDOI

Short- and Long-Term Mortality After Myocardial Infarction in Patients With and Without Diabetes: Changes from 1985 to 2008

TL;DR: Temporal mortality reductions after MI between 1985 and 2008 were at least as high in patients with diabetes compared with those without diabetes, however, long-term mortality remained higher in diabetic patients.
Journal ArticleDOI

Pre-hospital triage of patients with suspected myocardial infarction. Evaluation of previously developed algorithms and new proposals.

TL;DR: A new practical hospital admission model was developed, based on six clinical predictors, including analysis of an electrocardiogram, which may lead to better triage decisions by the general practitioner.
Journal ArticleDOI

Optimal intensity of oral anticoagulant therapy after myocardial infarction

TL;DR: If equal weight is given to hemorrhagic and thromboembolic complications, these results suggest that the optimal intensity of long-term anticoagulant therapy for myocardial infarction patients lies between 2.0 and 4.0.